| Details | | Publication Date: | 1993-05-01 | | Editor: | James H. Finke, Ronald M. Bukowski |
Publisher's Note
This reference brings together all aspects of renal cell carcinoma, and provides a basis for understanding the disease's origin, progression and responses to immunotherapy.;Examining the current status of cytokine, cell-based and chemotherapeutic methods of treatment, this book: discusses the clinical presentation of advanced renal carcinoma and its therapeutic challenges; reviews prognostic factors and the management of renal cell carcinoma occurring with von Hippel-Landau syndrome; summarizes efforts to identify the tumour suppressor gene deleted from chromosome 3 in most renal cell carcinomas; explicates the role of oncogenes in the progression of renal cell cancer and the molecular correlates of responses to interferon-alpha treatment; details the latest laboratory efforts to establish gene therapy for tumour treatment by transfection of cytokine genes in murine model systems; focuses on biologic response modifier therapy in humans, including cell-mediated immune responses and adoptive immunotherapy;
presents preclinical and clinical studies of interleukin-2 alone, in combination with othe cytokines, and with chemothrapeutic agents; and addresses studies on the tumour necrosis factor and low- and high-dose interferon-alpha.
Industry Reviews Chronicles the proceedings of an international symposium in 1991 (perhaps in Cleveland) reviewing the current knowledge about the immunology and molecular biology of renal cell carcinoma, the spontaneous regression of which is one of features that fascinate scientists. The 29 papers discuss clinical features, the molecular biology, cell-mediated immune response and adoptive immunotherapy, interleukin-2 and other cytones, and chemical, chemicoimmune, and combination therapies. Annotation copyright Book News, Inc. Portland, Or. Lockwood
| See an error? Submit a change request |